These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 8878127)
1. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Tönshoff G; Sippel C; Wolf H; Clausen M; Henze E Nucl Med Commun; 1996 Aug; 17(8):681-6. PubMed ID: 8878127 [TBL] [Abstract][Full Text] [Related]
2. [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy]. Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Kalina S; Clausen M; Henze E Nuklearmedizin; 1997 Apr; 36(3):103-9. PubMed ID: 9162904 [TBL] [Abstract][Full Text] [Related]
3. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy. Raza H; Khan AU; Hameed A; Khan A Nucl Med Commun; 2006 Jun; 27(6):495-9. PubMed ID: 16710103 [TBL] [Abstract][Full Text] [Related]
4. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133 [TBL] [Abstract][Full Text] [Related]
5. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401 [TBL] [Abstract][Full Text] [Related]
6. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer. Bohuslavizki KH; Klutmann S; Bleckmann C; Brenner W; Lassmann S; Mester J; Henze E; Clausen M Strahlenther Onkol; 1999 Feb; 175(2):57-61. PubMed ID: 10065139 [TBL] [Abstract][Full Text] [Related]
7. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up. Wu JQ; Feng HJ; Ouyang W; Sun YG; Chen P; Wang J; Xian JL; Huang LH Nucl Med Commun; 2015 Aug; 36(8):819-26. PubMed ID: 25932534 [TBL] [Abstract][Full Text] [Related]
8. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Malpani BL; Samuel AM; Ray S Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):535-40. PubMed ID: 8655377 [TBL] [Abstract][Full Text] [Related]
9. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. Bohuslavizki KH; Klutmann S; Brenner W; Mester J; Henze E; Clausen M J Clin Oncol; 1998 Nov; 16(11):3542-9. PubMed ID: 9817273 [TBL] [Abstract][Full Text] [Related]
10. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Caglar M; Tuncel M; Alpar R Clin Nucl Med; 2002 Nov; 27(11):767-71. PubMed ID: 12394122 [TBL] [Abstract][Full Text] [Related]
11. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial. Bohuslavizki KH; Klutmann S; Jenicke L; Kröger S; Buchert R; Mester J; Clausen M Cancer Biother Radiopharm; 1999 Oct; 14(5):337-47. PubMed ID: 10850318 [TBL] [Abstract][Full Text] [Related]
12. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer. Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360 [TBL] [Abstract][Full Text] [Related]
13. Salivary gland scintigraphy after radioiodine therapy. Malpani BL; Samuel AM; Jaiswar RK Nucl Med Commun; 1998 Feb; 19(2):183-4. PubMed ID: 9548203 [No Abstract] [Full Text] [Related]
14. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. Solans R; Bosch JA; Galofré P; Porta F; Roselló J; Selva-O'Callagan A; Vilardell M J Nucl Med; 2001 May; 42(5):738-43. PubMed ID: 11337569 [TBL] [Abstract][Full Text] [Related]
15. [Salivary gland damage after 131I therapy in patients with differentiated thyroid cancer. Preliminary report]. Macioszek A; Baczyk M; Kopeć T; Sowiński J Endokrynol Pol; 2008; 59(5):403-10. PubMed ID: 18979451 [TBL] [Abstract][Full Text] [Related]
16. Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic (amifostine) obtained in a rabbit animal model. Bohuslavizki KH; Klutmann S; Jenicke L; Brenner W; Feyerabend B; Henze E; Clausen M Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):181-6. PubMed ID: 10477022 [TBL] [Abstract][Full Text] [Related]
18. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer. Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767 [TBL] [Abstract][Full Text] [Related]
19. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322 [TBL] [Abstract][Full Text] [Related]
20. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk. Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663 [No Abstract] [Full Text] [Related] [Next] [New Search]